The Incremental Prognostic Value of Baseline <sup>18</sup>F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma

Wang, Hui; Yu, Wenjing; Wu, Tao; Xue, Yangyang; Zhang, Dan; Xu, Huiqin

doi:https://doi.org/10.1155/2020/4502489

BioMed Research International

On this page

Abstract Introduction Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Clinical Study | Open Access

Volume 2020 | Article ID 4502489 | https://doi.org/10.1155/2020/4502489

The Incremental Prognostic Value of Baseline ¹⁸F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma

Hui Wang,¹Wenjing Yu,¹Tao Wu,¹Yangyang Xue,¹Dan Zhang,¹and Huiqin Xu¹

Academic Editor: Rosario Caltabiano

Received05 Mar 2020

Revised08 May 2020

Accepted19 May 2020

Published08 Jun 2020

Abstract

Background and Purpose. Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma with rapid disease progression and poor prognosis. The aim of this study was to determine the incremental prognostic value of baseline ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in addition to clinical prognostic factors. Methods. From January 2010 to October 2019, a total of 23 patients who pathologically confirmed to have AITL were retrospectively analyzed. All patients underwent whole-body ¹⁸F-FDG PET/CT scan before chemotherapy. The ¹⁸F-FDG PET/CT features, clinical data, laboratory indicators, Ki67 labeling index, and survival status were collected and analyzed. Results. The median follow-up was 22 months. The expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively. The median overall survival (OS) was 23 months (95% confidence interval (CI): 8.459~37.541). AITL is prone to extranodal infiltration, in addition to nodal infiltration (6 patients had nodal infiltration alone, and 17 patients had both nodal and extranodal infiltration). The SUV_max of nodal lesions were higher than that for the extranodal lesions (, , , , ). On multivariate survival analysis, the Eastern Cooperative Oncology Group (ECOG) and SUV_max of extranodal lesions were independent predictors of OS. Conclusion. Baseline ¹⁸F-FDG PET/CT results and SUV_max of extranodal lesions showed an incremental prognostic value in addition to clinical prognostic factors.

1. Introduction

Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma diagnosed according to the World Health Organization (WHO) criteria presented in 2001. AITL accounts for approximately 1-2% of non-Hodgkin’s lymphoma and 15-20% of peripheral T-cell lymphoma (PTCL) with unique clinical, imaging, and pathological features [1]. AITL has the characteristics of rapid disease progression and poor prognosis. The early symptoms of the disease are not obvious, and patients are in the clinical stage III/IV at the time of diagnosis. The clinical course of AITL is complex and the treatment response is different. Humeniuk et al. [2] reported a case of AITL that went into spontaneous remission, an uncommon occurrence. Besides, the majority of AITL patients showed an aggressive course and dismal outcome with current therapies [1, 3]. Studies showed that ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is a rapidly evolving hybrid imaging technique in evaluation of infection and cancer; however, it has been rarely applied for predicting outcome of AITL. Therefore, additional information on the predictive value of the PET could be of great significance, especially in association with AITL patients’ OS. The ¹⁸F-FDG PET/CT features, clinical data, laboratory indicators, Ki-67 labeling index, and survival status of 23 patients with AITL were retrospectively analyzed in the present study.

2. Study Subjects and Methods

2.1. Study Subjects

A total of 23 AITL patients who underwent pretreatment ¹⁸F-FDG PET/CT from January 2010 to October 2019 were enrolled in the present study. Inclusion criteria were set as follows: (1) histopathologically confirmed as AITL; (2) all other nodal or extranodal lesions were proven to be AITL infiltrations based on image examination and clinical follow-up; and (3) availability of imaging and nonimaging data for staging. Patients with secondary malignant tumor were excluded. This study was approved by the Ethics Committee of The First Affiliated Hospital Of Anhui Medical University. Informed consent was waived because of the nature of this retrospective study.

2.2. Observational Indicators

Sex, age, first symptoms, history of autoimmune disease, lactate dehydrogenase (LDH), albumin, C-reactive protein (CRP), beta 2-microglobulin (β₂-MG), bone marrow biopsy, international prognostic index (IPI), and Ki-67 labeling index were collected and analyzed. Patients’ basic characteristics are summarized in Table 1.

Ann Arbor staging system was used, and the physical condition was scored as 1~5 according to the Eastern Cooperative Oncology Group (ECOG). The final follow-up deadline was February 2020, and the medical records available in hospital or telephone follow-up were checked. The overall survival (OS) was defined as time from diagnosis to date of death due to any cause or date of last follow-up contact for patients who were alive.

2.3. PET/CT Scanning Protocol

All patients underwent whole-body ¹⁸F-FDG PET/CT scans using a Siemens Biograph TruePoint PET/CT scanner (Siemens AG, Munich, Germany). After 6 h of fasting, PET/CT scan was carried out at 50~60 min after intravenous administration of 3.70~5.55 MBq/kg of ¹⁸F-FDG, with radiochemical purity >95% (Nanjing Jiangyuan Andike Positron Research and Development Co., Ltd., Nanjing, Jiangsu, China). Blood glucose level was monitored before scanning to ensure that the mentioned level was less than 11.0 mmol/l. The CT parameters were as follows: 120 kV, 80 mA, and PET acquisition was performed at 1 min per bed position for body and 2.5 min per bed position for head. All PET/CT images were interpreted by two experienced nuclear physicians retrospectively using a standard workstation (Syngo MMWP; Siemens AG, Munich, Germany). Focal or diffuse FDG uptake above background in a location mismatched with normal anatomy or physiology was interpreted as abnormal and indicative of a lymphoma lesion. The maximum standardized uptake values (SUV_max) were determined on PET scans.

2.4. Statistical Analysis

Herein, SPSS 17.0 software (IBM, Armonk, NY, USA) was used to carry out statistical analysis. Continuous variables were presented as (SD) or median (range) as appropriate. Qualitative variables were expressed as number (%). The optimal diagnostic critical values of SUV_max and Ki67 labeling index were obtained by using receiver operating characteristic (ROC) curve (Table 2). OS was determined by Kaplan-Meier analysis, and differences among the groups were analyzed by the log-rank test. Cox proportional hazards model was used for multivariate survival analysis. A was considered as statistically significant.

3. Results

3.1. Patients’ Outcome and Related Clinical Data

The median age of the 23 patients was 65 years old (range, 29~79 years old), and male : female ratio was 1.56 : 1. The most common presenting symptom was superficial mass (13 cases, 56.52%), followed by fever, cough, expectoration, rash, sore throat, abdominal distention, and abdominal pain. Besides, 6 (26.09%) cases had autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and urticarial vasculitis.

Ann Arbor staging system showed that 20 cases were at stage III~IV. The ECOG score >1 was found in 5 cases. Additionally, 12 cases had an international prognostic index (IPI) score at the range of 3~5. Moreover, elevated LDH and CRP levels were noted in 18 and 23 cases, respectively; the increased β₂-MG level was found in 18 cases; the low level of albumin was detected in 17 cases; was found in 15 cases; and 8 cases had serous cavity effusion as well.

3.2. ¹⁸F-FDG PET/CT Imaging Findings

The imaging findings of ¹⁸F-FDG PET/CT unveiled that all 23 AITL patients had nodal infiltration (6 patients had nodal infiltration alone, and 17 patients had both nodal and extranodal infiltration). No patient had extranodal infiltration alone. Lymphoma lesions showed positive uptake of ¹⁸F-FDG (Figures 1 and 2). The distribution of ¹⁸F-FDG PET/CT in AITL patients with nodal infiltration was as follows: (i) multiple lymph nodes with scattered distribution were observed in 21 patients and (ii) localized distribution: only 2 patients were affected by diaphragmatic ipsilateral lymph nodes, including abdominopelvic cavity, retroperitoneum, and iliac vascular region.

(a)

(b)

(c)

(d)

(e)

(a)

(b)

(c)

(d)

(e)

The SUV_max of the lymph node infiltration lesions and extranodal lesions was and , respectively. The SUV_max of nodal lesions was higher than that of extranodal lesions (, , ).

The most common extranodal organs or sites were spleen (14 cases), nasopharynx (9 cases), tonsil (7 cases), bone (4 cases), gut (1 case), lung (2 cases), pleura (4 cases), and skin and muscle (1 case). Invasion of spleen was detected in 14 cases, of whom, increased diffuse FDG uptake and no change in density in CT scan were detected. Additionally, no change in bone destruction or bone marrow cavity was found in patients with bone invasion. Notably, two cases with focal lesions on PET/CT scan were confirmed to have false-negative results of bone marrow biopsy.

3.3. Survival and Prognosis Analysis

The expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively. The median OS was 23 months (95% CI: 8.459~37.541). The log-rank analysis showed that , serous cavity effusion, , , and the were adverse prognostic factors of AITL () (Figure 3). On multivariate survival analysis, ECOG and SUV_max of extranodal lesions were independent predictors of OS (Table 3).

4. Discussion

AITL is a rare subtype of peripheral T-cell lymphoma with rapid disease progression and poor prognosis. In the present study, the expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively, and the median OS was 23 months (95% CI: 8.459~37.541). Similarly in the previous studies, the 5-year survival rate of AITL patients was lower than 40% [4, 5]. Xu and Liu [6] conducted a large population-based study using the Surveillance, Epidemiology, and End Results (SEER) program (1973-2010) to determine the temporal survival trends and prognostic factors for AITL patients. The results revealed that there was no survival improvement in AITL patients over the past two decades.

¹⁸F-FDG-PET/CT plays a pivotal role in the assessment of malignant lymphoma. However, a limited number of scholars concentrated on its application in the prognosis of AITL. The present study disclosed that AITL is prone to extranodal infiltration, in addition to nodal infiltration. AITL never caused extranodal infiltration alone in the current research. In addition, patients with extranodal infiltration typically exhibited infiltration in multiple organs, and the most common organs to develop infiltration were the spleen and nasopharynx, followed by the tonsil, bone, lung, pleura, skin, and muscle. This feature is similar to the published reports of PET in the management of AITL patients [1]. High cell turnover and high ¹⁸F-FDG avidity were noted in the majority of AITL patients demonstrated in the literature [7, 8]. In our study, the SUV_max of the lymph node infiltration lesions and extranodal lesions were and , respectively. Shao et al. [9] reported the SUV_max of lesions with lymph node infiltration and extranodal organ infiltration in AITL patients were 5.4-25.1 (median, 9.7) and 1.5-12.5 (median, 5.5), respectively. This could explain the high aggressiveness of AITL.

¹⁸F-FDG-PET/CT has been recommended for prognostic analysis for malignant lymphoma [10]. In the current research, baseline ¹⁸F-FDG-PET/CT results, SUV_max of extranodal lesions, and ECOG were independent predictors of OS on multivariate survival analysis. So far, SUV_max was the most widely studied parameter with promising results. Gallicchio et al. [11] demonstrated that a baseline predicts a poor outcome in patients with diffuse large B-cell lymphoma. In addition to SUV_max, Deauville score scale and semiquantitative and quantitative PET/CT parameters including metabolic tumor value (MTV) and total lesion glycolysis (TLG) have been demonstrated good results in prediction of response and prognosis in lymphomas. Deauville Criteria (DC) which is based on the application of a five-point scale using the mediastinum and liver activity as the reference standard has been demonstrated good results in prediction of response and prognosis in lymphomas at interim and end-of-treatment PET/CT [12, 13]. Fallanca et al. [14] reported that a score of at least 4 (DC4) showed a high diagnostic accuracy and predicted value for Hodgkin lymphoma and non-Hodgkin lymphoma. More recently, MTV and TLG have been demonstrated prognostic role in survival outcome of many lymphomas at baseline PET/CT [15, 16]. Various MTV delineation methods have been reported such as , , and (PERCIST) [17, 18]. However, MTV and TLG seemed to be more suitable for solid tumors than diffuse hypermetabolic organs like the spleen and bone. We chose SUV_max as the evaluation index for AITL due to the characteristic of extranodal infiltration.

In the current research, the main demiological (gender, sex), B symptom, Ann Arbor stage, IPI score, laboratory indicators (LDH, Albumin, β2-MG), serous cavity effusion, histopathplogical (ki67 labeling index), SUV_max of infiltrated lymph nodes, and extranodal involvement >1 site were not associated with OS. Nevertheless, the prognostic factors of lymphoma are controversial. Tokunaga et al. [19] elucidated the clinicopathological characteristics and prognosis of AITL patients in Japan and found that patients’ age >60 years old elevated white blood cell (WBC) and IgA levels; the presence of anemia and thrombocytopenia and extranodal involvement at >1 site were significant prognostic factors for OS. Albano et al. [20] revealed that the end of treatment ¹⁸F-FDG PET/CT significantly associated with PFS, not with OS in mantle cell lymphoma. Similar to our results, Zhou et al. [21] reported that baseline SUV_max was independent predictors of OS in peripheral T-cell lymphomas (PTCL). Baseline ¹⁸F-FDG PET/CT seems to be advantageous in prognosis of AITL. The current research revealed that the metabolic information of extranodal lesions should be concerned by researchers.

The limitation of the current study was the number of patients who enrolled in this retrospective analysis. The incidence of AITL is rare; therefore, further multicenter researches need to be conducted.

5. Conclusions

AITL is highly aggressive with poor prognosis. The current research revealed that the metabolic information of extranodal lesions should be concerned by researchers. Baseline ¹⁸F-FDG PET/CT results and SUV_max of extranodal lesions showed an incremental prognostic value in addition to clinical prognostic factors.

Data Availability

The data used to support the finding of this study are available from the corresponding author upon request.

Conflicts of Interest

There are no conflicts of interest.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (grant nos. 81801736 and 81971643).

References

M. Federico, T. Rudiger, M. Bellei et al., “Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project,” Journal of Clinical Oncology, vol. 31, no. 2, pp. 240–246, 2013.
View at: Publisher Site | Google Scholar
M. S. Humeniuk, J. J. Liang, M. Howard, and D. J. Inwards, “Spontaneous complete remission of angioimmunoblastic T-cell lymphoma,” Proceedings (Baylor University. Medical Center), vol. 27, no. 3, pp. 242–245, 2017.
View at: Publisher Site | Google Scholar
D. Jesionek-Kupnicka, M. Braun, T. Robak, W. Kuncman, and R. Kordek, “A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification,” Advances in Clinical and Experimental Medicine, vol. 28, no. 10, pp. 1359–1365, 2019.
View at: Publisher Site | Google Scholar
H. Hong, X. Fang, Z. Wang et al., “Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study,” Leukemia & Lymphoma, vol. 59, no. 12, pp. 2911–2916, 2018.
View at: Publisher Site | Google Scholar
Y. Li, C. Yang, L. Mao, J. Wang, C. Li, and W. Qian, “Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor,” Medicine (Baltimore), vol. 96, no. 39, article e8091, 2017.
View at: Publisher Site | Google Scholar
B. Xu and P. Liu, “No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases,” PLoS One, vol. 9, no. 3, article e92585, 2014.
View at: Publisher Site | Google Scholar
M. A. Lunning and J. M. Vose, “Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma,” Blood, vol. 129, no. 9, pp. 1095–1102, 2017.
View at: Publisher Site | Google Scholar
S. H. Moon, A. Y. Lee, W. S. Kim et al., “Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma,” Leukemia & Lymphoma, vol. 58, no. 6, pp. 1341–1348, 2017.
View at: Publisher Site | Google Scholar
D. Shao, Q. Gao, C. H. Liang, and S. X. Wang, “Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma,” Leukemia & Lymphoma, vol. 58, no. 7, pp. 1581–1588, 2017.
View at: Publisher Site | Google Scholar
S. F. Barrington, N. G. Mikhaeel, L. Kostakoglu et al., “Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group,” Journal of Clinical Oncology, vol. 32, no. 27, pp. 3048–3058, 2014.
View at: Publisher Site | Google Scholar
R. Gallicchio, G. Mansueto, V. Simeon et al., “F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma,” European Journal of Haematology, vol. 92, no. 5, pp. 382–389, 2014.
View at: Publisher Site | Google Scholar
A. Biggi, A. Gallamini, S. Chauvie et al., “International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers,” Journal of Nuclear Medicine, vol. 54, no. 5, pp. 683–690, 2013.
View at: Publisher Site | Google Scholar
S. F. Barrington, W. Qian, E. J. Somer et al., “Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1824–1833, 2010.
View at: Publisher Site | Google Scholar
F. Fallanca, P. Alongi, E. Incerti et al., “Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 10, pp. 1837–1848, 2016.
View at: Publisher Site | Google Scholar
S. F. Barrington and M. Meignan, “Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden,” Journal of Nuclear Medicine, vol. 60, no. 8, pp. 1096–1102, 2019.
View at: Publisher Site | Google Scholar
L. Ceriani, L. Milan, P. W. M. Johnson et al., “Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 6, pp. 1334–1344, 2019.
View at: Publisher Site | Google Scholar
J. H. Liang, Y. P. Zhang, J. Xia et al., “Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on ¹⁸F-FDG PET-CT in patients with follicular lymphoma,” Cancer Research and Treatment, vol. 51, no. 4, pp. 1479–1487, 2019.
View at: Publisher Site | Google Scholar
D. Albano, G. Bosio, C. Pagani et al., “Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 1, pp. 87–96, 2019.
View at: Publisher Site | Google Scholar
T. Tokunaga, K. Shimada, K. Yamamoto et al., “Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan,” Blood, vol. 119, no. 12, pp. 2837–2843, 2012.
View at: Publisher Site | Google Scholar
D. Albano, G. Bosio, N. Bianchetti et al., “Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma,” Annals of Nuclear Medicine, vol. 33, no. 7, pp. 449–458, 2019.
View at: Publisher Site | Google Scholar
Y. Zhou, X. Zhang, H. Qin et al., “Prognostic values of baseline ¹⁸F-FDG PET/CT in patients with peripheral T-cell lymphoma,” BioMed Research International, vol. 2020, 10 pages, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Hui Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1130

Downloads

1110

Citations